2023 World Conference on Lung Cancer (Posters)-EP07.04. Diagnosis, Treatment Patterns and Outcomes in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) in China

EP07.04. Diagnosis, Treatment Patterns and Outcomes in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) in China - PDF(Slides)

Back to course

Pdf Summary

This study aimed to analyze the diagnosis, treatment patterns, and outcomes of patients with RET fusion-positive non-small cell lung cancer (NSCLC) in China. The study utilized real-world data from three hospitals in the Chinese Multi-Centre Lung Cancer Precision Medicine Registry.<br /><br />Key findings from the study include:<br /><br />1. RET fusions are rare oncogenic drivers, found in approximately 1-2% of NSCLC cases in China.<br /><br />2. Biomarker testing for RET fusion was most often performed at the time of initial NSCLC diagnosis, regardless of the stage of diagnosis. Next-generation sequencing (NGS) was the most commonly used methodology for biomarker testing.<br /><br />3. The most common fusion gene partner for RET was KIF5B.<br /><br />4. In the advanced NSCLC subgroup, platinum-based chemotherapy alone was the primary systemic therapy in the first-line setting. It was often used in combination with monoclonal antibodies.<br /><br />5. The median real-world progression-free survival (PFS) at the first-line setting was 9.22 months for patients receiving chemotherapy alone and 10.55 months for patients receiving immune checkpoint inhibitors (ICIs).<br /><br />6. The median overall survival (OS) from the date of advanced stage diagnosis was 30.7 months.<br /><br />In conclusion, this study provides insights into the diagnosis patterns, treatment patterns, and outcomes of RET fusion-positive NSCLC patients in China. The findings highlight the use of biomarker testing and the effectiveness of different treatment strategies in this patient population.

Asset Subtitle

Shun Lu

Meta Tag

Speaker Shun Lu

Topic Early-Stage NSCLC: Progress in Pathology

Keywords

RET fusion-positive NSCLC

diagnosis

treatment patterns

outcomes

China

biomarker testing

KIF5B

advanced NSCLC

chemotherapy

immune checkpoint inhibitors